Highlights Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Real-time Estimate Cboe BZX Other stock markets 11:01:32 09/05/2024 pm IST			5-day change	1st Jan Change
29.72 ^USD	+0.25%		+9.46%	-11.37%

08/05	Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating	MT
07/05	Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pacira BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q1 Revenue $167.1M, vs. Street Est of $165.7M	08/05	MT
Pacira BioSciences, Inc. announces an Equity Buyback for $150 million worth of its shares.	08/05	CI
Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024	08/05	CI
Pacira BioSciences, Inc. authorizes a Buyback Plan.	07/05	CI
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	13/03	CI
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	29/02	MT
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	29/02	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	29/02	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	29/02	MT
North American Morning Briefing : Fed's Preferred -2-	29/02	DJ
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy	15/02	CI
Pacira BioSciences Receives Brand Pharmaceuticals Agreement With Premier, Inc	07/02	CI
Pacira BioSciences Says Preliminary Data Show 2023 Sales Rose 1.2% From Year Earlier, Topping Consensus	05/01	MT
Pacira BioSciences Says US FDA Approves Exparel Application for Two Additional Nerve Block Indications	10/11	MT
Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications	10/11	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q3 Revenue $163.9M, vs. Street Est of $172.9M	02/11	MT
Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023	02/11	CI
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Highlights

Filters